Skip to main content

Novavax begins early-stage trial for combined influenza and COVID-19 vaccine

Share

Vaccine developer Novavax said on Wednesday it has initiated an early-stage study to test its combined flu and COVID-19 vaccine.

The trial, to be conducted in Australia, will enroll 640 healthy adults between the ages of 50 and 70 years and who have either been previously infected with the coronavirus or given an authorized COVID-19 vaccine at least eight weeks prior to the study.

Participants will receive a combination of the company's COVID-19 vaccine candidate, NVX-CoV2373, and its Influenza shot NanoFlu along with an adjuvant or vaccine booster.

"Combination of these two vaccines...may lead to greater efficiencies for the healthcare system and achieve high levels of protection against COVID-19 and influenza with a single regimen," Gregory Glenn, president of research and development at Novavax, said in a statement.

Novavax had said in May it expects seasonal influenza and COVID-19 combination vaccines to likely be critical in combating emerging COVID-19 variants. Its vaccine NanoFlu/NVX-CoV2373 had elicited robust responses to both influenza A and B and protected against the coronavirus in pre-clinical studies.

Novavax expects the trial results in the first half of 2022.

CTVNews.ca Top Stories

BUDGET 2024

BUDGET 2024 Feds cutting 5,000 public service jobs, looking to turn underused buildings into housing

Five thousand public service jobs will be cut over the next four years, while underused federal office buildings, Canada Post properties and the National Defence Medical Centre in Ottawa could be turned into new housing units, as the federal government looks to find billions of dollars in savings and boost the country's housing portfolio.

Local Spotlight

Stay Connected